TORONTO—Bedrocan Cannabis Corp. has been given the final nod from Health Canada on its domestic production facility in Toronto. The company’s plant is now fully licensed across all 34 vegetative and growing rooms as well as three dispensing rooms and a two-floor security vault. The facility also has the ability to dispose of cannabis refuse via composting.
Bedrocan has been obtaining health Canada approvals for the growth and sale of its products over the course of the year.
“We are excited to be able to provide Canadian-grown, standardized cannabis to our registered patients,” Marc Wayne, the company’s president and CEO said after a similar announcement last month.
“We have now transitioned our business successfully and on schedule from our reliance on imported Bedrocan product to managing our own domestic production to meet the specific needs of our growing population of medical cannabis patients. We will now focus on expanding our marketing, medical outreach and education initiatives, emphasizing the value and advantages of our standardized, pharmaceutical grade medical cannabis products,” he added.
Bedrocan was acquired by Tweed Marijuana Inc. in June in a deal that will create Canada’s largest medical marijuana company. The Toronto marijuana grower will become a subsidiary of Tweed pending shareholder and court approval. The deal is expected to close at the end of August.
Despite the management changes on the horizon and now being fully licensed, the company is already looking to continue its growth. Bedrocan is moving forward with plans to increase capacity further. It has filed an application for an increase in maximum production and sale capacity that will be processed by Health Canada separately from this decision.